Vanda Pharmaceuti…
USUSDVanda Pharmaceuticals Inc (LSE:0LKB) — Biotechnology: Pharmaceutical Preparations. Number of exchanges where the company shares trade: 2. On this page — price and chart, dividends, top holders and share count history.
About the company
- Website
- vandapharma.com
- Investor relations
- vandapharma.com/investors
- Sector
- Health Care · Biotechnology: Pharmaceutical Preparations
- Headquarters
- WASHINGTON, United States
- Management
- Mihael H. Polymeropoulos
- Employees
- 533
- Listed since
- 29.01.2018 (LSE:0LKB)
- Shares outstanding
- Free float
- 47.66 M
- Market cap
- 276.31 M USD
- Insiders
- 6.78%
- Institutions
- 86.46%
- Industry (SIC)
- Pharmaceutical Preparations
- P/E
- 15.1
- P/B
- 1.10
- FCF
- −143 M USD
- Debt
- ?
- Earnings and FCF — for the 12 months to 30.06.2026 (the company's latest report).
- Net income
- NAV
Description
Vanda Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of therapies to address high unmet medical needs worldwide. The company's commercial portfolio includes Fanapt for the acute treatment of manic or mixed episodes associated with bipolar I disorder and the treatment of schizophrenia; HETLIOZ to treat non-24-hour sleep-wake disorders and nighttime sleep disturbances; PONVORY to treat relapsing forms of multiple sclerosis; and NEREUSTM for preventing vomiting induced by motion. It also develops Fanapt (iloperidone), a long acting injectable (LAI) formulation for the treatment of schizophrenia and hypertension; BysantiTM (milsaperidone), for the acute treatment of manic or mixed episodes associated with bipolar I disorder, and for the treatment of schizophrenia and major depressive disorder; HETLIOZ (tasimelteon) to treat jet lag disorder, insomnia, pediatric insomnia, delayed sleep phase disorder, and pediatric Non-24; PONVORY (ponesimod) to treat psoriasis and ulcerative colitis; and NEREUSTM (tradipitant) for prevention of vomiting induced by GLP-1 receptor agonists, as well as treatment of gastroparesis and atopic dermatitis. In addition, the company's products include Imsidolimab, an IL-36R antagonist to treat generalized pustular psoriasis; VTR-297, for the treatment of hematologic malignancies and onychomycosis, and several oncology indications; and VQW-765, small molecule alpha-7 nicotinic acetylcholine receptor partial agonist for the treatment of social/performance anxiety and psychiatric disorders. Further, it develops cystic fibrosis transmembrane conductance regulator activators and inhibitors; and antisense oligonucleotide molecules. The company was incorporated in 2002 and is headquartered in Washington, the District of Columbia.
Top holders
| Holder | Stake | Shares | Report date |
|---|---|---|---|
| Blackrock Inc. | 12.66% | 7.65 M | 2026-06-30 |
| State Street Corporation | 5.82% | 3.52 M | 2026-06-30 |
| AQR Capital Management,… | 5.78% | 3.5 M | 2026-06-30 |
| Renaissance Technologies… | 5.69% | 3.44 M | 2026-06-30 |
| POLYMEROPOULOS MIHAEL HR… | ≈4.47% | 2.7 M | 2026-03-02 |
| Vanguard Capital Managem… | 4.17% | 2.52 M | 2026-06-30 |
| SPDR SERIES TRUST-State… | 4% | 2.42 M | 2026-08-31 |
| AIGH Capital Management… | 3.38% | 2.04 M | 2026-06-30 |
| Acadian Asset Management… | 3.17% | 1.92 M | 2026-06-30 |
| VANGUARD INDEX FUNDS-Van… | 2.91% | 1.76 M | 2026-06-30 |
| Dimensional Fund Advisor… | 2.86% | 1.73 M | 2026-06-30 |
| Millennium Management Ll… | 2.65% | 1.6 M | 2026-06-30 |
| Geode Capital Management… | 2.45% | 1.48 M | 2026-06-30 |
| iShares Trust-iShares Ru… | 2.29% | 1.38 M | 2026-08-31 |
| Federated Hermes MDT Ser… | 1.79% | 1.08 M | 2026-07-31 |
| VANGUARD INDEX FUNDS-Van… | 1.16% | 703 761 | 2026-06-30 |
| Fidelity Salem Street Tr… | 0.97% | 585 865 | 2026-07-31 |
| iShares Trust-iShares Ru… | 0.85% | 510 983 | 2026-08-31 |
| BIRZNIEKS GUNTHER (Offic… | ≈0.82% | 494 197 | 2026-03-02 |
| BlackRock Funds-BlackRoc… | 0.81% | 489 961 | 2026-05-31 |
| iShares Trust-iShares Bi… | 0.7% | 425 246 | 2026-08-31 |
| MORAN KEVIN PATRICK (Chi… | ≈0.68% | 412 015 | 2026-03-02 |
| WILLIAMS TIMOTHY IAN (Ge… | ≈0.62% | 377 450 | 2026-03-02 |
| WIJKSTROM JOAKIM PER (Of… | ≈0.55% | 333 469 | 2026-03-02 |
| DFA INVESTMENT DIMENSION… | 0.55% | 333 667 | 2026-07-31 |
| DUGAN RICHARD W (Directo… | ≈0.36% | 219 054 | 2026-06-04 |
| CHROUSOS PHAEDRA (Direct… | ≈0.27% | 164 950 | 2026-06-04 |
| WARD ANNE SEMPOWSKI (Dir… | ≈0.27% | 160 667 | 2026-06-04 |
| HONORE TAGE (Director) | ≈0.22% | 135 069 | 2026-06-04 |
| MITCHELL STEPHEN RAY (Di… | ≈0.19% | 112 846 | 2026-06-04 |
Sign in with Google